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Abstract: Background: Low bone mineral density (BMD) is common in chronic lung diseases and associated with re-
duced quality of life. Little is known about BMD in pulmonary hypertension (PH). 
Methods: Steroid-naïve patients with PH (n=34; 19 idiopathic, 15 chronic thromboembolic) had BMD measured by DXA 
at the time of diagnostic right heart catheterization. Exercise capacity, quality of life and various parameters related to PH 
severity and bone metabolism were also assessed. 24 patients with left heart failure (LHF) were similarly assessed as con-
trols. 
Results: The prevalence of osteopenia was high both in PH (80%) and in controls with LHF (75%). Low BMD was asso-
ciated with lean body mass, age, lower BMI, impaired exercise capacity and in PH with higher pulmonary vascular resis-
tance. Serum parathyroid hormone (PTH) was elevated and considerably higher in PH than in LHF (above normal, in 55 
vs 29%). Secondary hyperparathyroidism was not related to impaired renal function but possibly to low vitamin D status. 
Conclusions: Osteopenia is common in PH and in chronically ill patients with LHF. Osteopenia is associated with known 
risk factors but in PH also with disease severity. Preventive measures in an increasingly chronic ill PH population should 
be considered. Secondary hyperparathyroidism is highly prevalent in PH and might contribute to bone and possibly pul-
monary vascular disease. Whether adequate vitamin D substitution could prevent low BMD in PH remains to be deter-
mined. 
Keywords:  Pulmonary hypertension, chronic thromboembolic pulmonary hypertension, hyperparathyroidism, osteopenia, 
osteoporosis, left heart failure. 
INTRODUCTION 
  Low bone mineral density (BMD) is a common condition 
in patients with end-stage heart and lung disease independent 
of the underlying diagnosis [1, 2]. While some of the risk 
factors such as low body mass index (BMI) are shared by 
most patients with severe pulmonary disease, others are 
more prevalent in specific lung diseases, such as history of 
smoking and systemic glucocorticoid use in chronic obstruc-
tive pulmonary disease and malnutrition in patients with 
cystic fibrosis [1, 2]. Little attention has been paid to low 
BMD in patients with pulmonary hypertension (PH). PH 
represents a group of relatively rare disorders, whereby dif-
ferent pulmonary vascular alterations such as vasoconstric-
tion, endothelial and smooth muscle cell proliferation, 
thrombosis and inflammation result in sustained elevated 
pulmonary vascular resistance and pulmonary arterial pres-
sure [3, 4]. Although PH is still an incurable disease, thera-
peutic advances in the last years have improved the life ex-
pectancy of patients [5-7]. Consequently, the management of 
clinical problems associated with chronic lung diseases such  
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as low BMD has become increasingly important in the care 
of PH-patients. Osteopenia has been found in nearly 60% of 
patients with idiopathic pulmonary arterial hypertension 
(IPAH) awaiting lung transplantation [2, 8]. Consistent with 
general population studies and the known impact of muscle 
mass and physical activity on BMD [9-11], a positive corre-
lation of both the body mass index (BMI, to some extent 
reflecting muscle mass) and the walking distance with the 
BMD was documented in some studies of patients with 
IPAH awaiting transplantation [2, 8, 12]. The pathogenetic 
mechanisms leading to decreased bone mass in end-stage PH 
are not known. Apart from general risk factors such as BMI 
and exercise capacity, other factors such as secondary hyper-
parathyroidism or disturbed vitamin D metabolism due to 
cardiac cirrhosis or a genetic background may play a role. 
Germline mutations in the bone morphogenetic protein re-
ceptor II (BMPR-II) gene (BMPR-2) have been described in 
familial and sporadic forms of PH [13-15]. Individual BMPs 
are key regulators of organogenesis [16], and were originally 
discovered based on their property to induce bone formation. 
Therefore, a contribution of the BMP signalling pathways to 
the pathogenesis of both pulmonary arterial vessel and bone 
disease could be hypothesized. However, the known clinical 
phenotype resulting from impaired BMPR-2 signalling is 
IPAH whereas an impact on the turnover of bone tissue has 54    The Open Respiratory Medicine Journal, 2009, Volume 3  Ulrich et al. 
not been found thus far. Considering that PH resulting from 
thromboembolic disease (CTEPH) occurs in patients with a 
comorbid and genetic background distinct from that in 
IPAH, the aim of the present study was to investigate the 
prevalence of osteoporosis/osteopenia in patients with PH in 
general and according to classification and to look for corre-
lations of the BMD with pulmonary haemodynamics, demo-
graphics, exercise performance, quality of life (QoL) and 
parameters related to calcium metabolism, bone turnover and 
disease severity. Since we aimed to see whether changes in 
bone and calcium metabolism in PH patients are unique or 
merely related to impaired exercise capacity with loss of 
muscle mass, we compared the prevalence of osteoporo-
sis/osteopenia between PH and similarly exercise-limited 
patients with left heart failure (LHF). 
MATERIAL AND METHODOLOGY 
Subjects 
  Consecutive patients with IPAH or CTEPH seen at our 
PH clinic were prospectively included upon written informed 
consent. PH was defined as mean pulmonary arterial pres-
sure (mPAP)  25 mmHg with a pulmonary capillary occlu-
sion pressure (PCOP)  15 mmHg by right heart catheterisa-
tion. IPAH was diagnosed if a thorough evaluation by medi-
cal history, echocardiography, rheumatologic examination, 
antibody screening and additional tests according to best 
clinical practice did not reveal any other causes for the ele-
vated pulmonary pressure [4]. CTEPH was diagnosed by 
both, radioisotope ventilation-perfusion scan and pulmonary 
angiography [17]. All patients had all investigations within 
two months of their heart catheter and had a 6 minute walk 
distance (6MWD) between 150 and 500 meters. Control 
patients with LHF with a similar 6MWD between 150-500 
meters were recruited upon written informed consent from 
our heart centre. The controls were investigated similarly 
except for haemodynamics by catheter. The study was ap-
proved by our ethics committee. 
Demographics, History, Exercise Performance and Qual-
ity of Life 
  Patient’s demographics (age, sex, height, weight and 
calculated body mass index [BMI in kg/m
2]), history and 
lifestyle with emphasis on nutrition, calcium intake, smok-
ing, drug use and history of bone fractures were assessed. 
Patients taking corticosteroids were excluded. NYHA func-
tional class, 6MWD and Borg dyspnoea scale score were 
assessed. Quality of life (QoL) was assessed by the Minne-
sota living with hearth failure questionnaire [18]. 
Osteoporosis Work-Up 
  BMD was measured by dual-energy X-ray absorptiome-
try (DXA) with the QDR 4500 A (Hologic Inc, Waltham, 
MA)  according to standard protocol at three sites: total 
proximal hip area (hip), the non-dominant femoral neck (FN) 
and the lumbar spine (LS). DXA images at the lumbar spine 
were reviewed by the same two experienced technicians 
(experience of 8 and 11 years) and vertebral bodies affected 
by degenerative changes were excluded from the analysis. 
The results were expressed in grams per square centimetre 
(g/cm
2) and in T-scores (numbers of standard deviations 
below the peak bone mass for an ethnically comparable age- 
and gender-matched reference population, as provided by the 
manufacturer). Osteoporosis and osteopenia were defined 
according to WHO (T-Sore  -2.5 respectively -1.0 to -2.5). 
In agreement with the International Society for Clinical Den-
sitometry (ISCD) guidelines, the lowest measured value in 
either spine or hip was considered. Whole body composition 
(LBM, fat and bones) was measured during the same proce-
dure. Chest X-rays were screened for vertebral fractures of 
the thoracic spine. 
Analysis in Blood and Urine 
  Calcium, phosphate, creatinine, uric acid, bone-specific 
alkaline phosphatase (ostase®), albumin, bilirubin, total 
testosterone (men), estradiol (amenorrhoic women) and NT-
pro brain natriuretic peptide (NT-pro-BNP) were determined 
(Roche; Rotkreuz; Switzerland). Intact parathyroid hormone 
(PTH) and C-reactive protein by sensitive method (CRPsens) 
were measured (Immulite 2000; DPC; Los Angeles; USA). 
25-hydroxyvitamin D was measured by radioimmunoassay 
(DiaSorin; Saluggia; Italy). Albumin-adjusted serum calcium 
was obtained as: calcium (mmol/l)-0.02*[albumin(g/l)-40]. 
The glomerular filtration rate was calculated by using the 
corrected MDRD formula [19]. Whole blood was automati-
cally analyzed for erythrocyte, leukocyte and thrombocyte 
counts. Urinary deoxypyridinoline (Immulite 2000; DPC; 
Los Angeles; USA) and calcium were analyzed in a second 
morning urine and expressed relative to urinary creatinine. 
Statistical Analysis 
  Results are expressed as mean ± standard deviations. The 
Mann Whitney-U test was used to compare means between 
groups (IPAH and CTEPH such as PH and LHF). Pearson’s 
product moment correlation and Spearman’s rho were used 
to correlate BMD and T-scores with demographics, pulmo-
nary haemodynamics, exercise performance and QoL and 
laboratory values. Multiple linear regression was used to 
study associations between the diagnosis PH and 
BMD/BMC and PTH corrected for possible confounders 
(age, sex, BMI, creatinine clearance, serum levels of cal-
cium, phosphate and vitamin D). Outcome-parameters were 
normalized using log-transformation. Differences showing p-
values < 0.05 were considered statistically significant. 
RESULTS 
Patient’s Characteristics 
 PH-study  group: We included 19 patients (13 females) 
with IPAH (age 64±15 years) and 15 patients (9 females) 
with CTEPH (age 65±12 years) in the study (Table 1). Most 
patients were in NYHA class III and IV. IPAH patients had a 
significantly lower 6MWD (342±87 m) compared with 
CTEPH (424±62 m, p=0.004) with a similar Borg dyspnoea 
scale and decline in oxygen saturation during the test. The 
mean mPAP, CI and PVR were comparable between IPAH 
and CTEPH (Table 1). 
  Control group with LHF: 24 patients (9 females), age 
67±12 with left heart disease (7=valvular, 8=ischemic, 
9=myocardial) were included as controls. Most of them were 
in NYHA class III and IV (Table 1) and walked slightly less 
than PH-patients (6MWD 288±92 m, p<0.001). The total Osteopenia and Hyperpara in PH  The Open Respiratory Medicine Journal, 2009, Volume 3    55 
QoL and its physical subscore were comparable between PH 
and LHF, but the emotional subscore was lower in LHF 
controls. 
  None of the patients reported a history of bone fracture 
and all patients had a minimum calcium intake of 1000 mg. 
Chest x-ray analysis revealed asymptomatic vertebral frac-
tures in two women with PH (6%) and one man with LHF 
(4%). PH specific drugs used in IPAH and CTEPH were 
inhaled iloprost (16 and 20%), bosentan (63 and 66%) and 
sildenafil (42 and 33%). Other drugs reported in IPAH, 
CTEPH and LHF included loop diuretics (58, 87, 79 %), 
thiazides (10, 7, 12%), phenprocoumon (100, 100, 50%), low 
dose aspirin (5, 13, 32%), angiotensin converting enzyme 
inhibitors and/or angiotensin receptor blockers (26, 27, 92 
%), beta-blockers (16, 7, 58%), calcium-channel blockers 
(32, 27, 13%), nitrates (5, 7, 17%), statins (21, 20, 37.5%), 
proton-pump-inhibitors (26, 33, 17%), serotonin-reuptake-
inhibitors (16, 7%, 8%). 
Prevalence of Osteoporosis and Osteopenia 
  About half of the patients with PH had osteopenia and 
one quarter had osteoporosis, with no significant difference 
between IPAH and CTEPH (Fig. 1, Table 2). The overall 
prevalence of osteoporosis/osteopenia was similar in the 
LHF controls but the mean BMD and T-scores tended to be 
lower in PH, especially at the hip (p=ns, Fig. 1, Table 2). 
The total bone mineral content (BMC) was lower in both 
PH-groups compared to LHF (p=0.052). LBM and fat were 
comparable in PH and LHF (Table 2). 
 
Analysis in Blood and Urine 
 General  parameters: Mean pro-BNP levels were mark-
edly elevated without any difference between groups (Table 
3). Mean CRPsens was significantly higher in LHF com-
pared with PH (p=0.007). Mean total protein and albumin 
levels were lower in LHF than in PH (p<0.001, Table 3). 
Mean uric acid levels were above the normal limit without 
difference between groups. Parameters reflecting kidney 
function were slightly impaired in all groups. 
  Parameters related to bone metabolism: Serum calcium, 
phosphate and sex hormone levels were within normal limits 
in all groups. Phosphate was higher in LHF (p=0.009), 
whereas serum PTH, ostase and urinary calcium were higher 
in PH (p=0.027, 0.002, 0.031). 25-hydroxyvitamin D levels 
were <10 g/l in 21 % of the patients with PH and in 8 % of 
LHF-controls. PTH levels were above the reference range in 
55% of patients with PH (IPAH 47%, CTEPH 67%) and 
29% of LHF (Fig. 2, p=0.044). Mean PTH serum levels and 
urinary calcium excretion did not differ between patients 
taking or not taking loop diuretics. Urinary deoxypyridino-
line excretion was equally elevated in both, PH and LHF 
patients. 
Correlations of BMD with Clinical Parameters in PH 
 With  sex: The BMD (total, g/cm
2 and T-scores) measured 
at the hip was significantly lower in females than in males 
(p<0.001). 
 With  age:  We found a significant negative correlation 
between age and BMD (g/cm
2 and T-scores) measured at the 
FN (r = -0.315 and -0.29; p=0.009 and 0.016). 
Table 1.  Characteristics of PH-Patients and Controls 
 






PAH vs CTEPH  
(p-Values) 
PH vs LHF  
(p-Values) 
General  
Sex (females/males)  13 / 6  9 / 6  9 / 15  0.724  0.061 
Age (years)  64 (15)  65 (12)  67 (12)  0.891  0.543 
NYHA functional class (II / III / IV)  1/ 9 / 9  1/ 10 / 4  1/ 10 / 13  0.102  0.655 
6 minute walk distance (m)  342 (87)  424 (62)  288 (93)  0.004*  <0.001** 
QoL total (points)  44 (3)  37 (17)  42 (21)  0.226  0.766 
QoL physical subscore (points)  24 (7)  21 (5)  24 (10)  0.062  0.258 
QoL emotional subscore (points)  9 (6)  9 (7)  6 (7)  0.890  0.027* 
Pulmonary Haemodynamics* 
Mean pulmonary arterial pressure (mm Hg)  48 (11)  42 (10)    0.199   
Pulmonary vascular resistance (dyne*s*cm
5)  760 (408)  724 (298)    0.953   
Cardiac Index (l/min/m
2)  2.2 (0.2)  2.0 (0.5)    0.529   
Mixed venous oxygen saturation (%)  58 (10)  54 (8)    0.132   
Arterial oxygen saturation (%)  90 (5)  88 (4)    0.065   
* p<0.05, **p<0.001. 
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  With body composition: BMI and LBM positively corre-
lated with T-scores at the hip and FN. 
  With pulmonary haemodynamics: PVR negatively corre-
lated with BMD measured at the hip (r=-0.254 resp -0.267; 
p=0.039 and 0.03 for g/cm
2 and T-scores) and LS (r=-0.305 
and -0.300; p=0.013 resp 0.014). 
  With exercise performance and QoL: We found a posi-
tive correlation of the 6MWD with the BMD only in CTEPH 
at the hip (r=0.308, p=0.034). 
  With different clinical chemistry parameters: We found a 
weak positive correlation of LS-BMD (g/cm
2 and T-scores) 
with serum creatinine (r=0.24 resp 0.23; p=0.049 resp 0.05) 
and a negative correlation with ostase (r=-0.243 resp -0.283; 
p=0.048 resp 0.02). 
 Multivariate  analysis: In a multiple linear regression 
model including age, sex, BMI and the serum levels of cal-
cium, phosphate and PTH as co-factors we found a trend to-
wards lower BMD and BMC for patients with PH compared 
to LHF (PH around 2.5%, p=ns). 
 
Fig. (1). Proportion of patients with osteoporosis, osteopenia and normal BMD. BMD = bone mineral density, IPAH = idiopathic pulmonary 
arterial hypertension. CTEPH = chronic thromboembolic pulmonary hypertension, LHF = left heart disease, FN = femoral neck, LS = lumbar 
spine. 
Table 2.  BMD and Body Composition Results by DXA 
 
  IPAH (n=19)  CTEPH (n=15)  LHF-Controls (n=24)  PAH vs CTEPH (p-Values)  PH vs LHF (p-Values) 
Osteoporosis / Osteopenia (n, %)  5 / 10 (26/53)  4 / 8 (27/53)  6 / 12 (25/50)     
T-score hip  -1.03 (1.09)  -0.95 (1.23)  -0.62 (0.87)  0.656  0.179 
T-score FN  -1.34 (1.16)  -1.39 (1.16)  -0.91 (0.886)  0.655  0.092 
T-score LS  -1.20 (1.70)  -1.23 (1.61)  -1.03 (1.62)  0.973  0.482 
Total body bone mineral content (kg)  2.06 (4.8)  2.26 (5.6)  2.94 (2.7)  0.391  0.052 
Lean body mass (kg)  48.0 (6.4)  48.5 (8.9)  51.8 (12.8)  0.973  0.377 
Fat (kg)  22.6 (9.9)  21.1 (7.7)  25.4 (11.7)  0.811  0.151 
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Correlations of PTH with Clinical Parameters in PH 
  PTH correlated positively with ostase (r=0.301; 
p=0.017), albumin (r=0.343; p=0.008), uric acid (r=0.258; 
p=0.038), the CI (r=0.279; p=0.027) and the PCOP (r=0.262; 
p=0.04) and negatively with 25-OH-vitamin D (r=-0.314, 
p=0.011). 
 Multivariate  analysis: In a multiple linear regression 
model including age, sex, BMI, glomerular filtration rate and 
serum levels of calcium, phosphate and vitamin D as possi-
ble confounders we still found that the diagnosis of PH was 
associated with higher PTH serum levels (p=0.05). 
DISCUSSION 
  In the present study we found a high prevalence of osteo-
porosis/osteopenia in PH, but also in patients suffering from 
LHF. A T-score of < -1.0 was present in approximately 80% 
of the patients, without any difference between the IPAH and 
CTEPH. Higher age, female gender, low body weight, sex 
hormone deficiency, sedentary life style, decreased calcium 
intake and extended corticosteroid use are accepted risk 
factors for osteopenia in the general population [11]. Os-
teopenia affects not only the elderly but also patients suffer-
ing from gastrointestinal, liver and kidney diseases [20-23]. 
As for lung diseases, an association with low BMD has been 
found in COPD, cystic fibrosis and other end stage diseases 
[2, 8, 24, 25]. Our finding of a high incidence of osteopenia 
in PH-patients might have important clinical implications.   
 
 
Fig. (2). Parathyroid hormone levels in patients with PH and LHF. 
PH = pulmonary hypertension, PTH = parathyroid hormone,   
LHF = left heart disease. Open circles, idiopathic pulmonary arte-
rial hypertension (IPAH), closed circles chronic thromboembolic 
pulmonary hypertension (CTEPH). 
Low BMD is associated with increased morbidity and re-
duced quality of life [26]. Interestingly, our patients did not 
reported bone fractures despite the low BMD and only 6% 
Table 3.  Blood and Urine Analysis 
 
  IPAH (n=19)  CTEPH (n=15)  LHF-Controls 
(n=24) 
PAH vs CTEPH 
(p-Values) 
PH vs Controls 
(p-Vlaues) 
General  
pro-BNP (<88 ng/L)  2500 (1874)  2256 (1505)  3617 (3501)  0.97  0.224 
C-reactive protein (<1 mg/l)  9.2 (9.5)  10.4 (10.4)  16.9 (13.6)  0.957  0.007* 
Uric Acid (150-300 mol/L)  460 (172)  471 (147)  488 (178)  0.762  0.79 
Creatinine (Cr) (44-80 mol/L)  110 (38)  95 (9)  114 (33)  0.228  0.209 
GFR MDRD (> 60 ml/min/m
2)***  47 (16)  51 (11)  47 (13)  0.376  0.764 
Albumin (34-48 g/l)  44 (10)  42 (4)  38 (3)  0.631  <0.001** 
Bone Metabolism 
Calcium, alb-adj.(2.09-2.54 mmol/L)****  2.32 (0.2)  2.24 (0.1)  2.19 (0.4)  0.157  0.515 
Phosphate (0.87-1.45 mmol/L)  0.99 (0.2)  1.02 (0.2)  1.21 (0.3)  0.246  0.009* 
Ostase (3.4-9.8 g/L)  15.3 (6)  14.9 (6)  10.7 (6)  0.800  0.002* 
PTH (15-65 ng/L)  88 (71)  93 (45)  56 (23)  0.331  0.027* 
25-Hydroxy-Vitamin D (10-42 g/L)  15 (6)  15 (8)  19 (10)  0.556  0.137 
Urinary calcium/creatinine ( 0.1-0.5 mmol/mmol)  0.47 (0.42)  0.62 (0.64)  0.30 (0.31)  0.794  0.031* 
Urinary deoxypyridinoline/creatinine (2.5-5 nmol/mmol)  7.87 (10.3)  7.63 (1.98)  8.64 (4.12)  0.710  0.676 
Normal values in brackets after parameters. Results given as means (SD). 
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revealed vertebral fractures in their chest x-ray. It might be 
that the relatively young age and exercise limitation due to 
PH reduced the risk for falls in this population. Consistent 
with other studies performed in patients with heart disease 
[27], we also found a high prevalence of low BMD in com-
parably exercise-limited patients with LHF (Table 2). 
  In line with previous studies, we found only a weak asso-
ciation between higher age and female gender with low 
BMD, and we confirm the particularly strong association 
between BMI and BMD [2]. We now extend these findings 
by showing an even more striking association with LBM, 
presumably even better reflecting muscle mass than BMI. By 
contrast, the 6MWD was less clearly related to BMD, possi-
bly as this test estimates the actual exercise capacity and 
does not the reflect the exercise capacity over time. 
  Interestingly, we found a negative correlation of the 
BMD with the PVR. The present results of a negative corre-
lation of BMD and PVR are consistent with our previous 
retrospective analysis of PH-patients awaiting lung trans-
plantation and demonstrate for the first time an association 
between pulmonary haemodynamics and BMD in a prospec-
tive study. Furthermore, a multivariate model corrected for 
common confounders showed a trend towards an association 
between the diagnosis of PH and lower BMC. For ethical 
concerns we did not have pulmonary hemodynamics by right 
heart catheterisation available in controls with LHF which is 
indeed a limitation of our study since we cannot rule out that 
some of the LHF controls could have elevated pulmonary 
artery pressures due to backpressure from pulmonary venous 
hypertension. Furthermore, our cross-sectional study could 
not fully estimate the impacts of disease severity and dura-
tion on BMD. Speculating about potential underlying patho-
genetic mechanisms, genetic mutations could favour the 
development of both PH and low BMD. However, the even 
stronger negative correlation of BMD with PVR in CTEPH 
patients compared with IPAH discourages the hypothesis of 
specific genetics contributing to both low BMD and in-
creased pulmonary artery pressure and rather suggests a 
relation between the disease severity with possible associ-
ated metabolic changes and low BMD. Another link between 
bone and PH might be the serotonin system which plays a 
pathogenetic role in various forms of PH [3] and more re-
cently has been reported to regulate bone mass [28]. Such 
potential pathogenetic links are certainly worth of further 
research. 
  Interestingly, we found a particularly striking elevation 
of the mean PTH serum levels in patients with PH (Table 3). 
An increased PTH was found in more than half of all PH 
patients (Fig. 2). PH seems to be a predictor of high PTH 
serum levels even in a multivariate model corrected for age, 
sex, BMI, serum calcium, phosphate and vitamin D levels. 
Elevated serum PTH levels have been described in patients 
with severe congestive LHF, and serum PTH has been 
shown to be a predictor of cardiovascular mortality in an 
elderly population, irrespective of the vitamin D status [27, 
29, 30]. Usually, elevated PTH in heart failure patients has 
been attributed to secondary hyperparathyroidism due to 
impaired renal function and/or induction by loop diuretics 
(due to hypercalciuria) [31]. However, hyperparathyroidism 
has also been demonstrated in LHF patients who did not 
receive loop diuretics [32]. 
  Regarding our PH patients, 70% (and 79% LHF) were 
treated with loop diuretics; we found no difference in mean 
PTH serum levels between loop diuretic-treated and not 
treated individuals in any group and also no relation to im-
paired renal function. It thus appears that neither increased 
creatinine nor diuretics account for high PTH levels, and that 
factors other than renal failure or drugs, possibly vitamin D 
deficiency, endothelial dysfunction or altered haemodynam-
ics, might be responsible for secondary hyperparathyroidism 
in PH. Serum levels of PTH have not only been described to 
be elevated in congestive heart failure, but also in a broad 
spectrum of critically ill patients in the emergency depart-
ment and have been shown to be related to disease severity 
and mortality [33]. Kidney disease is a classical cause of 
secondary hyperparathyroidism. In patients with chronic 
renal failure, values of PAP correlated directly with serum 
levels of PTH [34, 35]. Interestingly, PTH serum levels in 
PH correlated with the PCOP. The PCOP is the key hemo-
dynamic parameter to distinguish pulmonary arterial hyper-
tension from pulmonary venous hypertension as often seen 
in LHF. It therefore would have been of interest to know, if 
the PCOP would have correlated with PTH levels in LHF-
controls as well. Unfortunately, this hemodynamic data in 
the LHF-group is lacking and it remains unclear whether the 
relatively lower PTH levels in LHF in this study are associ-
ated with less elevated PCOP in this group. We found no 
significant correlation of the PTH with the pulmonary artery 
pressure or vascular resistance. Our finding of significantly 
increased serum PTH levels in patients with right heart fail-
ure merits attention; it may reflect a vascular problem or 
point towards a hormonal role of PTH in the vasculature. 
Secondary hyperparathyroidism, FN osteoporosis and hip 
fractures have been considered characteristic of osteoporosis 
in elderly patients [36]. In our PH patients, increased PTH 
correlated positively with bone-specific alkaline phosphatase 
and negatively with 25-hydroxyvitamin D levels. Therefore, 
inappropriate vitamin D status may contribute to both sarco-
penia and secondary hyperparathyroidism in PH. Indeed, the 
25-OH vitamin D levels in our cohort, although within the 
reference range in most of the patients, were low. We have 
no actual reasonably (age-, sex- and referral pattern-) 
matched reference cohort available; however, it is notewor-
thy that the mean 25-OH vitamin D levels in our PH patients 
were almost identical to those found in elderly (age 65+, 
mean >80years) patients admitted from home (from a com-
parable referral area, over the same time period, assessed 
with the same 25-OH vitamin D assay) to the hospital for hip 
fracture, considered severely vitamin D deficient [37]. It may 
well be that the high prevalence of low vitamin D levels 
found in PH contributes to secondary hyperparathyroidism. 
CONCLUSION 
  In summary, this cross-sectional study shows that low 
BMD is fairly common in both, IPAH and CTEPH, but also 
LHF. Increased awareness of osteopenia in PH might be 
important in order to prevent fractures and save QoL. The 
finding of increased serum levels of PTH in PH is novel and 
merits attention. Secondary hyperparathyroidism in our PH 
population was not associated to impaired renal function but 
possibly to inappropriate vitamin D status. Whether adequate 
vitamin D substitution may prevent secondary hyperparathy-
roidism and low BMD in PH remains to be determined. Osteopenia and Hyperpara in PH  The Open Respiratory Medicine Journal, 2009, Volume 3    59 
ABBREVIATIONS 
BMC =  Bone  mineral  content 
BMD =  Bone  mineral  density 
BMI =  Body  mass  index 
BMPR  =  Bone morphogenetic protein receptor 
BNP  =  Brain natriuretic peptide 
BSA =  Body  surface  area 
CI =  Cardiac  index 
COPD  =  Chronic obstructive pulmonary disease 
CRP =  C-reactive  protein 
CTEPH  =  Chronic thromboembolic pulmonary  
     hypertension 
FN =  Femoral  neck 
IPAH  =  Idiopathic pulmonary arterial hypertension 
LBM  =  Lean body mass 
LHF  =  Left heart disease 
LS =  Lumbar  spine 
mPAP  =  Mean pulmonary arterial pressure 
N =  Normal  value 
NYHA  =  New York Heart Association 
PCOP  =  Pulmonary capillary occlusion pressure 
PVR  =  Pulmonary vascular resistance 
PH =  Pulmonary  hypertension 
PTH =  Parathyroid  hormone 
QoL  =  Quality of Life 
TGF  =  Transforming growth factor 
6MWD  =  6 minute walk distance 
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